Position in JANX
as of Jun 30, 2026
· filed Jul 7, 2026
Position Value
$1,038,489
+$109,038 QoQ
Shares Held
67,610
+1.1% QoQ
Ownership
0.111%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#2
of 12 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 88%
Shared 0%
None 12%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CONGRESS ASSET MANAGEMENT CO holds $715,705,658 across 14 Biotechnology names. JANX ranks #13 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
659,911 | $208,591,267 | |
| 2 | TGTX |
Tg Therapeutics, Inc.
|
2,600,123 | $142,850,757 | |
| 3 | VCEL |
Vericel Corp
|
2,916,295 | $129,745,964 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
1,229,106 | $96,202,126 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
265,701 | $79,983,972 | |
| 6 | KRYS |
Krystal Biotech, Inc.
|
40,134 | $14,916,603 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
380,746 | $11,902,119 | |
| 8 | RLAY |
Relay Therapeutics, Inc.
|
626,141 | $11,715,098 |
All Filings in JANX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,038,489 | 67,610 | Shares | Sole | 2026-07-07 | |
| 2026-03-31 | $929,451 | 66,867 | Shares | Sole | 2026-04-14 | |
| 2025-12-31 | $791,319 | 57,342 | Shares | Sole | 2026-01-09 | |
| 2025-09-30 | $1,363,092 | 55,773 | Shares | Sole | 2025-10-10 | |
| No filing history on record for this holder in this stock. | ||||||